A detailed history of Legal & General Group PLC transactions in Sana Biotechnology, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 168,000 shares of SANA stock, worth $268,800. This represents 0.0% of its overall portfolio holdings.

Number of Shares
168,000
Previous 168,000 -0.0%
Holding current value
$268,800
Previous $698,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.76 - $6.86 $10,813 - $19,729
2,876 Added 1.74%
168,000 $698,000
Q2 2024

Aug 14, 2024

BUY
$5.23 - $10.44 $300,604 - $600,059
57,477 Added 53.39%
165,124 $901,000
Q1 2024

Jul 01, 2024

BUY
$4.2 - $11.27 $24,792 - $66,526
5,903 Added 5.8%
107,647 $1.08 Million
Q1 2024

May 14, 2024

BUY
$4.2 - $11.27 $49,547 - $132,952
11,797 Added 13.12%
101,744 $1.02 Million
Q3 2023

Nov 14, 2023

SELL
$3.77 - $6.23 $3,294 - $5,445
-874 Reduced 0.96%
89,947 $348,000
Q2 2023

Aug 14, 2023

BUY
$3.22 - $7.53 $67,014 - $156,714
20,812 Added 29.73%
90,821 $541,000
Q1 2023

May 15, 2023

BUY
$3.11 - $4.92 $7,597 - $12,019
2,443 Added 3.62%
70,009 $228,000
Q3 2022

Nov 14, 2022

BUY
$5.58 - $9.04 $10,401 - $16,850
1,864 Added 2.84%
67,566 $406,000
Q2 2022

Aug 22, 2022

BUY
$4.12 - $9.35 $41,134 - $93,350
9,984 Added 17.92%
65,702 $422,000
Q1 2022

May 16, 2022

BUY
$5.24 - $15.58 $193,984 - $576,771
37,020 Added 197.99%
55,718 $461,000
Q4 2021

Feb 14, 2022

BUY
$15.18 - $23.15 $138,745 - $211,591
9,140 Added 95.63%
18,698 $290,000
Q3 2021

Nov 15, 2021

BUY
$16.29 - $25.88 $99,303 - $157,764
6,096 Added 176.08%
9,558 $215,000
Q2 2021

Aug 12, 2021

BUY
$16.65 - $32.14 $2,497 - $4,821
150 Added 4.53%
3,462 $68,000
Q1 2021

May 17, 2021

BUY
$23.04 - $43.5 $76,308 - $144,072
3,312 New
3,312 $111,000

Others Institutions Holding SANA

About Sana Biotechnology, Inc.


  • Ticker SANA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 190,232,000
  • Market Cap $304M
  • Description
  • Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others...
More about SANA
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.